Literature DB >> 8840222

IgH (mu-switch and gamma-1) region restriction fragment length polymorphism in human narcolepsy.

S M Singh1, C F George, R N Ott, C Rattazzi, C Guilleminault, W C Dement, E Mignot.   

Abstract

Predisposition to narcolepsy involves genetic factors both in humans and in a canine model of the disorder. In humans, narcolepsy is strongly associated with HLA DR15 and DQB1*0602. In Dobermans and Labradors, narcolepsy is transmitted as a single autosomal recessive gene with full penetrance (canarc-1). Canine narcolepsy is not linked with DLA, the canine equivalent of HLA, but co-segregates with a DNA segment with high homology with the mu immunoglobulin heavy-chain (IgH) switch-like region (S mu). To determine if the IgH locus is involved in genetic predisposition to human narcolepsy, restriction fragment length polymorphisms specific for the IgM and IgG cluster within this locus were studied in sporadic cases of the disease, as well as in five families with two or more affected individuals. Comparisons were made between control populations and both familial and sporadic cases and for patients with and without HLA-DR15 and DQB1*0602. RFLP analysis at the S mu and gamma-1 loci, which cover over 200 kb of 14q32.3, indicates that there is no evidence for any association between the IgH region and human narcolepsy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840222     DOI: 10.1007/bf01541226

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  27 in total

1.  Restriction fragment length polymorphism in canine narcolepsy.

Authors:  M Motoyama; T S Kilduff; B S Lee; W C Dement; H O McDevitt
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

2.  Ig gamma restriction fragment length polymorphisms indicate an ancient separation of Caucasian haplotypes.

Authors:  M J Johnson; G de Lange; L L Cavalli-Sforza
Journal:  Am J Hum Genet       Date:  1986-05       Impact factor: 11.025

3.  CSF immune variables in patients with narcolepsy.

Authors:  S Fredrikson; B Carlander; M Billiard; H Link
Journal:  Acta Neurol Scand       Date:  1990-03       Impact factor: 3.209

4.  Susceptibility to multiple sclerosis associated with an immunoglobulin gamma 3 restriction fragment length polymorphism.

Authors:  C N Gaiser; M J Johnson; G de Lange; L Rassenti; L L Cavalli-Sforza; L Steinman
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

5.  Twin studies in narcolepsy.

Authors:  M Partinen; C Hublin; J Kaprio; M Koskenvuo; C Guilleminault
Journal:  Sleep       Date:  1994-12       Impact factor: 5.849

6.  Family studies in narcolepsy.

Authors:  M Billiard; V Pasquié-Magnetto; M Heckman; B Carlander; A Besset; Z Zachariev; J F Eliaou; A Malafosse
Journal:  Sleep       Date:  1994-12       Impact factor: 5.849

7.  An immunoglobulin switchlike sequence is linked with canine narcolepsy.

Authors:  E Mignot; R A Bell; C Rattazzi; M Lovett; F C Grumet; W C Dement
Journal:  Sleep       Date:  1994-12       Impact factor: 5.849

8.  Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems.

Authors:  E Mignot; S Nishino; L H Sharp; J Arrigoni; J M Siegel; M S Reid; D M Edgar; R D Ciaranello; W C Dement
Journal:  J Neurosci       Date:  1993-03       Impact factor: 6.167

9.  DQB1-0602 (DQw1) is not present in most nonDR2 Caucasian narcoleptics.

Authors:  E Mignot; X Lin; J Kalil; C George; S Singh; M Billiard; J Montplaisir; J Arrigoni; C Guilleminault; W C Dement
Journal:  Sleep       Date:  1992-10       Impact factor: 5.849

Review 10.  Narcolepsy and immunity.

Authors:  E Mignot; M Tafti; W C Dement; F C Grumet
Journal:  Adv Neuroimmunol       Date:  1995
View more
  1 in total

1.  IgG abnormality in narcolepsy and idiopathic hypersomnia.

Authors:  Susumu Tanaka; Makoto Honda
Journal:  PLoS One       Date:  2010-03-05       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.